Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 4/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460426 | 0.90 | CYP19A1 (0.48) | KCNA5VNN1OXTRCYP19A1AVPR1A | |
| SCHEMBL4466454 | 0.89 | CYP19A1 (0.48) | KCNA5VNN1OXTRCYP19A1AVPR1A | |
| SCHEMBL4472869 | 0.87 | CYP19A1 (0.48) | KCNA5OXTRCYP19A1AVPR1ACYP11B2 | |
| SCHEMBL4457212 | 0.86 | KCNA5 (0.42) | KCNA5OXTRCYP19A1AVPR1A | |
| SCHEMBL4459003 | 0.86 | CYP19A1 (0.49) | KCNA5VNN1CYP19A1KCNH2GRM5 | |
| SCHEMBL4461835 | 0.86 | CYP19A1 (0.40) | KCNA5OXTRCYP19A1AVPR1A | |
| SCHEMBL4472165 | 0.83 | CYP19A1 (0.45) | KCNA5OXTRCYP19A1AVPR1ACYP11B2 | |
| SCHEMBL4457675 | 0.83 | KCNA5 (0.41) | KCNA5OXTRCYP19A1GRM5 | |
| SCHEMBL4464219 | 0.83 | CYP19A1 (0.41) | KCNA5VNN1OXTRCYP19A1AVPR1A | |
| SCHEMBL4464233 | 0.81 | KCNA5 (0.35) | KCNA5OXTRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | KCNA5 11/4885VNN1 3240/4885OXTR 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.